United States · Bill · HR
H.R. 2297 (118th)
To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024.
Introduced
29 March 2023
Last action
—
Status
Referred to the Subcommittee on Health.
Sponsors
—
Subjects
Discovery layer
Source updated
24 July 2024
Summary
This bill limits FY2024 funding for the Food and Drug Administration (FDA) Innovation Account, which the FDA uses to implement provisions of the 21st Century Cures Act relating to the development of medical products.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 29 March 2023
Introduced in House (PDF)
Introduced in House · EN · 29 March 2023
Introduced in House
summary · EN · 29 March 2023
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/118th-congress/house-bill/2297
- Open data entity: https://api.congress.gov/v3/bill/118/hr/2297